Related Experiment Video
Updated: Jul 7, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors
G F Sud'ina1, M A Pushkareva, P Shephard
1A.N. Belozersky Institute of Physico-Chemical Biology of the Moscow State University, Leninskie Gory, Building A, 199991 Moscow, Russian Federation. sudina@genebee.msu.ru
Abstract:
In vitro evaluations of the selectivity of COX inhibitors are based on a great variety of experimental protocols. As a result, data available on cyclooxygenase (COX)-1/COX-2/5- lipoxygenase (LOX) selectivity of COX inhibitors lack consistency. We, therefore, performed a systematic analysis of the COX-1/COX-2/5-LOX selectivity of 14 compounds with selective COX inhibitory activity (Coxibs). The compounds belonged to different structural classes and were analyzed employing the well-recognized whole-blood assay. 5-LOX activity was also tested on isolated human polymorphonuclear leukocytes. Among COX inhibitors, celecoxib and ML-3000 (licofelone) inhibited 5-LOX in human neutrophils at micromolar ranges. Surprisingly, ML-3000 had no effect on 5-LOX product synthesis in whole-blood assay. In addition, we could show that inhibition of COX pathways did not increase the transformation of arachidonic acid by the 5-LOX pathway.
Related Concept Videos
Cycloaddition Reactions: MO Requirements for Thermal Activation
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Peroxisomes
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dose-Response Relationship: Selectivity and Specificity
Oxidation of Alkenes: Anti Dihydroxylation with Peroxy Acids